Allergan has a rich and promising early stage pipeline of new drugs and innovative new technologies. We are aggressively investing in our pipeline in anticipation of major product approvals in 2007 and beyond.

Our ophthalmology pipeline includes novel treatments for retinal diseases and drugs for glaucoma and dry eye disease. Back-of-the-eye diseases such as macular edema, diabetic retinopathy and age-related macular degeneration are a major strategic focus of this business. To combat diabetic and non-diabetic macular edema, we are conducting Phase III studies to investigate POSURDEX®, a proprietary formulation of dexamethasone contained in a novel bioerodable extended release drug delivery system that can deliver medications to the back of the eye for months following a single intraocular injection. In the battle against glaucoma, we are supporting the world’s largest Phase III clinical trial to investigate the potential use of a highly promising oral compound called memantine for protection against the damage caused by increased pressure on the back of the eye. If proven effective, memantine, in conjunction with current topical agents, would be the first and only oral medication that directly protects the optic nerve in the treatment of glaucoma.

Allergan has a rich and promising early stage pipeline of new drugs and innovative new technologies. We are aggressively investing in our pipeline in anticipation of major product approvals in 2007 and beyond.

Product	Indication	R&D Alliances	Pre-Clinical	Phase I	Phase II	Phase III	Review
ophthalmology
Combigan™	Glaucoma (IOP)	—					U.S.
Lumigan®/ Timolol	Glaucoma (IOP)	—					U.S./ E.U.
Memantine Oral	Glaucoma	—
Posurdex®	Retinal Vein Occlusion	—
Posurdex®	Diabetic Macular Edema	—
Triamcinolone	Diabetic Macular Edema	—
Triamcinolone	Retinal Vein Occlusion	—
Androgen Tear	Ocular Surface Disease	Schepens Eye Research Institute
Sirna 027	Age-Related Macular Degeneration	—
Diquafosol	Dry Eye	Inspire Pharmaceuticals					U.S.

BOTOX® holds promise for other debilitating diseases, and we are investigating a number of additional potential uses. Major Phase III clinical programs have been commenced to investigate the safety and efficacy of BOTOX® as a prophylactic therapy for patients with chronic daily headache and for those with idiopathic and neurogenic overactive bladder, and we are also investigating additional uses in post-stroke spasticity, benign prostatic hypertrophy and pain management. Our neurology pipeline is further focused on the “next generation” BOTOX® treatment with more selective action for pain management and spasticity treatment. And in late 2005, we started clinical trials investigating a unique class of alpha adrenergic agonists for neuropathic pain.

Allergan has a rich and promising early stage pipeline of new drugs and innovative new technologies. We are aggressively investing in our pipeline in anticipation of major product approvals in 2007 and beyond.

Product	Indication	R&D Alliances	Pre-Clinical	Phase I	Phase II	Phase III	Review
neurosciences
Botox®	Migraine Headache	—
Botox®	Spasticity Upper Limb	—				U.S.
Alpha Agonist	Neuropathic Pain	Acadia Pharmaceuticals

Promising projects in the medical aesthetics R&D pipeline include Inamed’s JUVÉDERM™, a next-generation hyaluronic acid which is expected to compete with the current world leader RESTYLANE® upon approval in the United States. Inamed completed its filing of a Pre-Market Approval (PMA) application for JUVÉDERM™ with the FDA in December 2005. JUVÉDERM™ is expected to receive approval in the United States in late 2006 or early 2007. In September 2005, Inamed received an approvable letter from the FDA for its filing of a PMA application for its responsive gel silicone breast implants. The same responsive gel implants, along with a new and unique BIODIMENSIONAL® Cohesive Gel Matrix implant, are under review by the FDA and Health Canada. The addition of the Allergan team, with our strong track record of R&D and bringing products to market, should strengthen the approval process as we move forward.

Allergan has a rich and promising early stage pipeline of new drugs and innovative new technologies. We are aggressively investing in our pipeline in anticipation of major product approvals in 2007 and beyond.

Product	Indication	R&D Alliances	Pre-Clinical	Phase I	Phase II	Phase III	Review
medical aesthetics
Botox®	Facial Aesthetics- Glabellar Lines	GlaxoSmithKline				Japan
Juvéderm™ — Non-animal based, cross linked hyaluronic acid-based dermal filler	Soft Tissue Augmentation — Correction of Facial Folds, Wrinkles, Lines	—					U.S.
Silicone Breast Implant — Responsive Gel	Breast Augmentation & Reconstruction	—					U.S.
Silicone Breast Implant — Cohesive Silicone Gel Matrix (style 410)	Breast Augmentation & Reconstruction	—					U.S.

The cornerstone of the Allergan skin care business is tazarotene, a retinoid approved for the treatment of acne and psoriasis under the brand name TAZORAC®. In addition to our approval of BOTOX® for primary axillary hyperhidrosis (severe underarm sweating), we are also conducting Phase III studies in the use of BOTOX® for the treatment of palmar hyperhidrosis (excessive sweating of hands or palms). We continue to invest in R&D aimed at building on our strong leadership position in this market.

Allergan has a rich and promising early stage pipeline of new drugs and innovative new technologies. We are aggressively investing in our pipeline in anticipation of major product approvals in 2007 and beyond.

Product	Indication	R&D Alliances	Pre-Clinical	Phase I	Phase II	Phase III	Review
medical dermatology
Botox®	Palmar Hyperhidrosis	—

Allergan continues to invest in new technologies and in our gastroenterology R&D pipeline. We have completed Phase I clinical trials for a new proton pump inhibitor pro-drug for the treatment of gastrointestinal disease.

Allergan has a rich and promising early stage pipeline of new drugs and innovative new technologies. We are aggressively investing in our pipeline in anticipation of major product approvals in 2007 and beyond.

Product	Indication	R&D Alliances	Pre-Clinical	Phase I	Phase II	Phase III	Review
gastroenterology
Pro-Omeprazole	GERD and Erosive Esophagitis	Winston Pharmaceuticals

Phase III clinical programs have been commenced to study the potential application of BOTOX® as a treatment for neurogenic overactive bladder (OAB). In addition, Allergan is conducting Phase II clinical trials for BOTOX® to treat idiopathic OAB. We are also investigating BOTOX® as a treatment for benign prostatic hypertrophy (BPH).

Allergan has a rich and promising early stage pipeline of new drugs and innovative new technologies. We are aggressively investing in our pipeline in anticipation of major product approvals in 2007 and beyond.

Product	Indication	R&D Alliances	Pre-Clinical	Phase I	Phase II	Phase III	Review
urology
Botox®	Overactive Bladder — Neurogenic	—
Botox®	Overactive Bladder — Idiopathic	—
Botox®	Benign Prostatic Hyperplasia	—